Rectocolita ulcerohemoragică este o afec iune inflamatorie cronică idiopatică a colonului, caracterizată printr-o inflama ie superficială difuză care implică întotdeauna rectul, cu grade variate de extensie la nivelul colonulul proximal. Boala nu afectează intestinul sub ire, deși un procent mic dintre pacien i pot prezenta o inflama ie superficială limitată a ileonului terminal. Clinic, boala se manifestă prin rectoragii, tenesme rectale și diaree. Severitatea bolii se evaluează luând în considera ie multipli factori, incluzând numărul de scaune, rectoragiile, aspectul endoscopic și efectele afec iunii asupra calită ii vie ii pacientului. Tratamentul rectocolitei ulcerohemoragice este adaptat la severitatea puseelor de activitate a bolii, fără să existe un tratament universal eficient. Deciziile de tratament trebuie să se bazeze pe activitatea bolii (ușoară, moderată, severă) și distribu ia acesteia (proctita, colită stânga, pancolită). În cazul formelor de boală ușoare până la moderate limitate la rect și la pacien ii cu colită stângă, baza tratamentului o constituie 5-aminosalicila ii, care sunt foarte eficien i ca tratament topic (supozitoare, clisme, spume). Corticosteroizii sunt indica i la pacien ii cu boală mai severă și în cazurile în care mesalazina a eșuat în inducerea remisiunii. Recomandarea terapeutică de bază pentru rectocolita ulcerohemoragică extinsă ușoară până la moderată constă într-o terapie combinată cu 5-aminosalicila i administra i oral și topic, combinarea celor două forme de administrare dovedindu-se superioară utilizării unice a oricăreia dintre acestea. Utilizarea corticosteroizilor sistemici trebuie luată în considerare mai devreme pentru pacien ii cu colită extinsă și / sau la care tratamentul cu 5-aminosalicila ii a eșuat. Terapia adecvată pentru pacien ii cu rectocolită ulcerohemoragică severă impune, în general, spitalizarea. În aceste cazuri, terapia cu corticosteroizi este încă standardul de aur. Dacă nu se observă nicio ameliorare sau simptomele se agravează după 72 de ore, se poate lua în considerare terapia conven ională de linia a doua sau proctocolectomia. La pacien ii refractari la corticosteroizi, precum și la pacien ii cu rectocolită ulcerohemoragică severă, introducerea precoce a medicamentelor imunosupresoare poate fi eficientă pentru prevenirea recăderilor și a complica iilor, cum ar fi megacolonul toxic. Fără îndoială, anticorpii anti-TNF au îmbunătă it op iunile terapeutice disponibile pentru pacien ii cu rectocolită ulcerohemoragică. Există, însă, un procent substan ial de pacien i care nu răspund la administrarea de anticorpi anti-TNF sau care pierd răspunsul la aceștia. Din fericire, pentru aceste cazuri, au fost dezvoltate noi clase de medicamente care se află în evaluare în diverse faze ale studiilor clinice. Pentru a ilustra heterogenitatea cazurilor de rectocolită ulcerohemoragică, prezentăm trei situa ii particulare.
The treatment of ulcerative colitis is adapted to the disease severity and to the individual patient, no treatment being universally effective. Treatment decisions should be based on disease activity (mild, moderate, severe) and distribution (proctitis, left-sided, extensive colitis).
If mild to moderate inflammation is limited to the rectum and for left-sided colitis, the mainstay on the treatment are 5-aminosalicylates, which are highly effective as a topical treatment (suppositories, enemas, foams). Corticosteroids are indicated in patients with more severe disease, and in cases where mesalamine has failed in inducing remission.
For extensive mild to moderate ulcerative colitis, therapy recommendation consists of a combined therapy using oral and topical 5-ASA, which proved to be superior to single use of either. Use of systemic corticosteroids should be considered earlier for patients with extensive colitis and/or treatment failure. For patients with severe ulcerative colitis, hospitalization is generally required. In these cases, steroid therapy is still the gold standard. If there is no improvement in the first 72 hours after the initiation of treatment or symptoms are worsening, second-line conventional therapy must be attempted or proctocolectomy may be considered. In steroid-refractory patients, as well as in patients with severe ulcerative colitis, early introduction of immunosuppressive drugs may be effective during severe episodes, and for the prevention of complications, such as toxic megacolon. Without doubt, the introduction of anti-TNF antibodies have improved the therapeutic options available for patients with ulcerative colitis. But, there still is a substantial amount of patients not responding to anti-TNF antibodies or experiencing a secondary loss of response. Fortunately, for these cases, new classes of drugs have been developed and have been evaluated in early clinical trials.
To illustrate the heterogeneity of cases of ulcerative colitis, we present three particular situations.
Keywords: ulcerative colitis, severity, treatment. Ulcerative colitis is usually diagnosed in late adolescence and early adulthood, although the diagnosis may be made at any age, and appears to affect both sexes equally . (1) Clinically the disease is associated with rectal bleeding and urgency, tenesmus, and diarrhea , symptoms being present usually (2) for a few weeks before the patient presents to the doctor . 
Stool specimens should be obtained to exclude common enteric pathogens, and especially C difficile. When suspecting ulcerative colitis, ileocolonoscopy with a minimum of two biopsies from the inflamed regions should be obtained . The exception (3) to this rule is severe colitis, in which case, due to the increased risk of bowel perforation, complete ileocolonoscopy is not usually recommended.
Severity assessment
In the assessment of the disease severity, various factors are used, including the frequency of bowel movements, rectal bleeding, laboratory tests, endoscopic extension and appearance and patient's quality of life . Mild disease is typically (2) considered to be characterized by fewer than 5 bowel movements per day and, not affecting in a negative way daily life.
On the other hand, moderate to severe disease is characterized by more frequent bowel movements (up to 10 per day), with bleeding, affecting daily activities, like patients' attendance at work or school.
Among objective clinical features, the most useful inpredisting the severity of the disease are bloody stool and frequency, body temperature, and heart rate . As for the (1) laboratory markers, the widely used acute phase C-reactive protein is not as useful in ulcerative colitis as it is in Crohn's disease for the assessment of disease activity . Among (1) the stool markers, the most used are faecal calprotectin and lactoferrin.
Taking into consideration the macroscopic extent at colonoscopy, ulcerative colitis is classified into proctitis (limited to the rectum), left sided colitis (the lesions limited to the splenic flexure) and extensive colitis ( e x t e n d i n g p r ox i m a l t o t h e s p e n i c flexure) (table 2) . Granularity, vascular pattern, ulceration, and bleeding and/or friability are endoscopic features predictive for disease severity , bleeding and friability (1) being included within the Mayo score for ulcerative colitis (table 3) .
The extension of the lesions evaluated at colonoscopy may underestimate the extent of disease as compared with histology . Clinical cases Table 2 . Distribution of UC * adapted from Silverberg et al (5) The introduction of biologic, antitumor necrosis factor alpha (anti-TNFα) therapies has been a great progress un the management of patients with inflammatory bowel diseases that are r e f r a c t o r y t o c o n v e n t i o n a l treatments . However, not all the (6) patients respond to these drugs, some loose their response over time, or are intolerant to these treatments (7) l Probiotics are being tried taking into 
Clinical cases

Activity-Adapted Therapy
The factors influencing treatment decisions should be disease activity (mild, moderate, severe) and endoscopic distribution of the lesions (proctitis, left-sided, extensive colitis).
Patients with Mild to Moderate Activity
l In patients with mild to moderate inflammation that is limited to the rectum, the first-line therapy consists of topical treatment with mesalamine.
The usual dosage is 1-g mesalamine suppositories given once daily.
Patients who fail to respond to this treatment require the addition of oral prednisolone . (1) l For mild to moderate disease thet is limited to the left-sided colon, the first line therapy consists of a combination of topical mesalamine enemas or foams 1 g/day and oral mesalamine (>2 g/day). If after two weeks of treatment there are no results, systemic steroids need to be given . 
